开云app官网登录入口网页版-官方正版

#Avastin#

17篇内容 | 1026人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1396143, encodeId=fe1513961430a, content=<a href='/topic/show?id=78393025f8' target=_blank style='color:#2F92EE;'>#Avastin#</a>, objectTitle=Cancer Commun：贝伐珠单抗生物类似物LY01008对比贝伐珠单抗(Avastin)一线治疗中国不可切除、转移或复发的非鳞状非小细胞肺癌患者的疗效和安全性:一项多中心、随机、双盲III期试验, objectType=article, longId=213612, objectId=25b221361280, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25b221361280, replyNumber=0, likeNumber=61, createdTime=2021-07-03, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25b221361280, moduleTitle=Cancer Commun：贝伐珠单抗生物类似物LY01008对比贝伐珠单抗(Avastin)一线治疗中国不可切除、转移或复发的非鳞状非小细胞肺癌患者的疗效和安全性:一项多中心、随机、双盲III期试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=25b221361280)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396142, encodeId=3e95139614234, content=<a href='/topic/show?id=78393025f8' target=_blank style='color:#2F92EE;'>#Avastin#</a>, objectTitle=Bio-Thera向欧洲药品管理局提交了Avastin生物仿制药BAT1706的营销授权申请（MAA）。, objectType=article, longId=203853, objectId=e1e7203853fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1e7203853fc, replyNumber=0, likeNumber=82, createdTime=2020-11-30, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1e7203853fc, moduleTitle=Bio-Thera向欧洲药品管理局提交了Avastin生物仿制药BAT1706的营销授权申请（MAA）。, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e1e7203853fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396141, encodeId=c7521396141ae, content=<a href='/topic/show?id=78393025f8' target=_blank style='color:#2F92EE;'>#Avastin#</a>, objectTitle=PD-L1单抗Tecentriq联合VEGF单抗Avastin：在中国获准治疗常见的肝癌患者, objectType=article, longId=202660, objectId=e6f9202660eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6f9202660eb, replyNumber=0, likeNumber=76, createdTime=2020-10-31, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6f9202660eb, moduleTitle=PD-L1单抗Tecentriq联合VEGF单抗Avastin：在中国获准治疗常见的肝癌患者, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e6f9202660eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396140, encodeId=8acf139614039, content=<a href='/topic/show?id=78393025f8' target=_blank style='color:#2F92EE;'>#Avastin#</a>, objectTitle=罗氏的Tecentriq/Avastin组合获得美国批准——用于无法切除或转移性肝癌的免疫疗法, objectType=article, longId=195322, objectId=25f219532272, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25f219532272, replyNumber=0, likeNumber=61, createdTime=2020-06-06, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25f219532272, moduleTitle=罗氏的Tecentriq/Avastin组合获得美国批准——用于无法切除或转移性肝癌的免疫疗法, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=25f219532272)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396139, encodeId=3a3d139613924, content=<a href='/topic/show?id=78393025f8' target=_blank style='color:#2F92EE;'>#Avastin#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq联合Avastin在III期肝癌试验中将死亡风险降低了40％以上, objectType=article, longId=183550, objectId=84a4183550aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84a4183550aa, replyNumber=0, likeNumber=80, createdTime=2019-11-26, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84a4183550aa, moduleTitle=罗氏的PD-L1单抗Tecentriq联合Avastin在III期肝癌试验中将死亡风险降低了40％以上, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=84a4183550aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396138, encodeId=95e21396138ee, content=<a href='/topic/show?id=78393025f8' target=_blank style='color:#2F92EE;'>#Avastin#</a>, objectTitle=罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功, objectType=article, longId=181787, objectId=0d52181e8763, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d52181e8763, replyNumber=0, likeNumber=73, createdTime=2019-10-24, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d52181e8763, moduleTitle=罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0d52181e8763)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396137, encodeId=58eb139613ee2, content=<a href='/topic/show?id=78393025f8' target=_blank style='color:#2F92EE;'>#Avastin#</a>, objectTitle=2019 ESMO：罗氏的PD-L1单抗Tecentriq与VEGF单抗Avastin联合针对无法切除的肝细胞癌患者的Ib期研究中显示出令人鼓舞的结果, objectType=article, longId=180179, objectId=775a1801e9d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=775a1801e9d4, replyNumber=0, likeNumber=89, createdTime=2019-09-29, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=775a1801e9d4, moduleTitle=2019 ESMO：罗氏的PD-L1单抗Tecentriq与VEGF单抗Avastin联合针对无法切除的肝细胞癌患者的Ib期研究中显示出令人鼓舞的结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=775a1801e9d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396136, encodeId=c6be139613681, content=<a href='/topic/show?id=78393025f8' target=_blank style='color:#2F92EE;'>#Avastin#</a>, objectTitle=辉瑞的Avastin生物仿制药——ZIRABEV在欧洲获批治疗多个转移性肿瘤, objectType=article, longId=160659, objectId=32b11606595c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32b11606595c, replyNumber=0, likeNumber=82, createdTime=2019-02-22, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32b11606595c, moduleTitle=辉瑞的Avastin生物仿制药——ZIRABEV在欧洲获批治疗多个转移性肿瘤, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=32b11606595c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396135, encodeId=8a9913961358a, content=<a href='/topic/show?id=78393025f8' target=_blank style='color:#2F92EE;'>#Avastin#</a>, objectTitle=罗氏向欧盟提起申请：Tecentriq与Avastin联合治疗肾细胞癌, objectType=article, longId=153843, objectId=27431538430e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27431538430e, replyNumber=0, likeNumber=109, createdTime=2018-11-20, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27431538430e, moduleTitle=罗氏向欧盟提起申请：Tecentriq与Avastin联合治疗肾细胞癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=27431538430e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396134, encodeId=8e1a13961340e, content=<a href='/topic/show?id=78393025f8' target=_blank style='color:#2F92EE;'>#Avastin#</a>, objectTitle=Avastin生物仿制药获得欧盟批准, objectType=article, longId=127348, objectId=5d1c12e348d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d1c12e348d0, replyNumber=0, likeNumber=103, createdTime=2018-01-24, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d1c12e348d0, moduleTitle=Avastin生物仿制药获得欧盟批准, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5d1c12e348d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396133, encodeId=b64413961337a, content=<a href='/topic/show?id=78393025f8' target=_blank style='color:#2F92EE;'>#Avastin#</a>, objectTitle=里程碑！欧盟批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌, objectType=article, longId=49147, objectId=a38a4914ee9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a38a4914ee9, replyNumber=0, likeNumber=75, createdTime=2015-04-10, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a38a4914ee9, moduleTitle=里程碑！欧盟批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a38a4914ee9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396132, encodeId=7d5c139613265, content=<a href='/topic/show?id=78393025f8' target=_blank style='color:#2F92EE;'>#Avastin#</a>, objectTitle=药品也跨界：罗氏癌症药物Avastin能治疗眼疾, objectType=article, longId=47532, objectId=786c4e532b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=786c4e532b4, replyNumber=0, likeNumber=70, createdTime=2015-03-02, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=786c4e532b4, moduleTitle=药品也跨界：罗氏癌症药物Avastin能治疗眼疾, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=786c4e532b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396131, encodeId=2509139613176, content=<a href='/topic/show?id=78393025f8' target=_blank style='color:#2F92EE;'>#Avastin#</a>, objectTitle=罗氏Avastin再获批 **用于晚期宫颈癌的生物药物, objectType=article, longId=43043, objectId=f21c43043db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f21c43043db, replyNumber=0, likeNumber=0, createdTime=2014-11-26, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f21c43043db, moduleTitle=罗氏Avastin再获批 **用于晚期宫颈癌的生物药物, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f21c43043db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396130, encodeId=1b5c139613025, content=<a href='/topic/show?id=78393025f8' target=_blank style='color:#2F92EE;'>#Avastin#</a>, objectTitle=FDA批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌, objectType=article, longId=39215, objectId=fcdb3921526, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcdb3921526, replyNumber=0, likeNumber=108, createdTime=2014-08-20, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcdb3921526, moduleTitle=FDA批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fcdb3921526)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396129, encodeId=d7fe13961297a, content=<a href='/topic/show?id=78393025f8' target=_blank style='color:#2F92EE;'>#Avastin#</a>, objectTitle=欧盟批准罗氏安维汀（Avastin）用于铂耐药复发性卵巢癌, objectType=article, longId=38832, objectId=1f85388327a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f85388327a, replyNumber=0, likeNumber=153, createdTime=2014-08-09, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f85388327a, moduleTitle=欧盟批准罗氏安维汀（Avastin）用于铂耐药复发性卵巢癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1f85388327a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396128, encodeId=23a0139612806, content=<a href='/topic/show?id=78393025f8' target=_blank style='color:#2F92EE;'>#Avastin#</a>, objectTitle=Avastin超标签用药真的可以吗？政府与药企到底谁在耍流氓？, objectType=article, longId=37547, objectId=aa3e3e547d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa3e3e547d5, replyNumber=0, likeNumber=127, createdTime=2014-07-10, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa3e3e547d5, moduleTitle=Avastin超标签用药真的可以吗？政府与药企到底谁在耍流氓？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=aa3e3e547d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396127, encodeId=898a139612e39, content=<a href='/topic/show?id=78393025f8' target=_blank style='color:#2F92EE;'>#Avastin#</a>, objectTitle=NCCN PK FDA：Avastin治疗乳腺癌的存废之争, objectType=article, longId=2967, objectId=3dce296edd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dce296edd, replyNumber=0, likeNumber=77, createdTime=2011-08-05, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dce296edd, moduleTitle=NCCN PK FDA：Avastin治疗乳腺癌的存废之争, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3dce296edd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

Avastin

2020-05-29

智者为医08 (审核中...)

前往app查看评论内容

#Avastin#

Cancer Commun：贝伐珠单抗生物类似物LY01008对比贝伐珠单抗(Avastin)一线治疗中国不可切除、转移或复发的非鳞状非小细胞肺癌患者的疗效和安全性:一项多中心、随机、双盲III期试验

2021-07-03

智者为医08 (审核中...)

前往app查看评论内容

#Avastin#

Bio-Thera向欧洲药品管理局提交了Avastin生物仿制药BAT1706的营销授权申请（MAA）。

2020-11-30

智者为医08 (审核中...)

前往app查看评论内容

#Avastin#

PD-L1单抗Tecentriq联合VEGF单抗Avastin：在中国获准治疗常见的肝癌患者

2020-10-31

智者为医08 (审核中...)

前往app查看评论内容

#Avastin#

罗氏的Tecentriq/Avastin组合获得美国批准——用于无法切除或转移性肝癌的免疫疗法

2020-06-06

智者为医08 (审核中...)

前往app查看评论内容

#Avastin#

罗氏的PD-L1单抗Tecentriq联合Avastin在III期肝癌试验中将死亡风险降低了40％以上

2019-11-26

智者为医08 (审核中...)

前往app查看评论内容

#Avastin#

罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功

2019-10-24

智者为医08 (审核中...)

前往app查看评论内容

#Avastin#

2019 ESMO：罗氏的PD-L1单抗Tecentriq与VEGF单抗Avastin联合针对无法切除的肝细胞癌患者的Ib期研究中显示出令人鼓舞的结果

2019-09-29

智者为医08 (审核中...)

前往app查看评论内容

#Avastin#

辉瑞的Avastin生物仿制药——ZIRABEV在欧洲获批治疗多个转移性肿瘤

2019-02-22

智者为医08 (审核中...)

前往app查看评论内容

#Avastin#

罗氏向欧盟提起申请：Tecentriq与Avastin联合治疗肾细胞癌

2018-11-20

智者为医08 (审核中...)

前往app查看评论内容

#Avastin#

Avastin生物仿制药获得欧盟批准

2018-01-24

智者为医08 (审核中...)

前往app查看评论内容

#Avastin#

里程碑！欧盟批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌

2015-04-10

智者为医08 (审核中...)

前往app查看评论内容

#Avastin#

药品也跨界：罗氏癌症药物Avastin能治疗眼疾

2015-03-02

智者为医08 (审核中...)

前往app查看评论内容

#Avastin#

罗氏Avastin再获批 **用于晚期宫颈癌的生物药物

2014-11-26

智者为医08 (审核中...)

前往app查看评论内容

#Avastin#

FDA批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌

2014-08-20

智者为医08 (审核中...)

前往app查看评论内容

#Avastin#

欧盟批准罗氏安维汀（Avastin）用于铂耐药复发性卵巢癌

2014-08-09

智者为医08 (审核中...)

前往app查看评论内容

#Avastin#

Avastin超标签用药真的可以吗？政府与药企到底谁在耍流氓？

2014-07-10

智者为医08 (审核中...)

前往app查看评论内容

#Avastin#

NCCN PK FDA：Avastin治疗乳腺癌的存废之争

2011-08-05

科室
- - 订阅+
  - 更多科室
工具
服务